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Abstract
Background: Epithelial to mesenchymal transition (EMT) has been connected with cancer progression in vivo and the
generation of more aggressive cancer cell lines in vitro. EMT has been induced in prostate cancer cell lines, but has
previously not been shown in primary prostate cells. The role of EMT in malignant transformation has not been clarified.
Methodology/Principal Findings: In a transformation experiment when selecting for cells with loss of contact inhibition,
the immortalized prostate primary epithelial cell line, EP156T, was observed to undergo EMT accompanied by loss of
contact inhibition after about 12 weeks in continuous culture. The changed new cells were named EPT1. EMT of EPT1 was
characterized by striking morphological changes and increased invasion and migration compared with the original EP156T
cells. Gene expression profiling showed extensively decreased epithelial markers and increased mesenchymal markers in
EPT1 cells, as well as pronounced switches of gene expression modules involved in cell adhesion and attachment.
Transformation assays showed that EPT1 cells were sensitive to serum or growth factor withdrawal. Most importantly, EPT1
cells were not able to grow in an anchorage-independent way in soft agar, which is considered a critical feature of
malignant transformation.
Conclusions/Significance: This work for the first time established an EMT model from primary prostate cells. The results
show that EMT can be activated as a coordinated gene expression program in association with early steps of transformation.
The model allows a clearer identification of the molecular mechanisms of EMT and its potential role in malignant
transformation.
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Introduction
Epithelial to mesenchymal transition (EMT) is a developmental
process characterized by loss of epithelial markers, gain of
mesenchymal markers and changes in cellular morphology and
phenotype with increased ability to migrate and invade [1–3].
EMT is an important physiological process during embryogenesis
and wound healing, but may be exploited to play a central role in
cancer progression (reviewed in [2,4–7]). During progression to
metastatic competence, carcinoma cells acquire mesenchymal
adhesive properties and the activation of proteolysis and motility,
which allows the tumor cells to metastasize and establish
secondary tumors at distant sites [3–5]. Several models have been
proposed to show that EMT contributes to the progress of
established tumours in transformed cells [6,8,9]. The relationship
between EMT and early carcinogenesis has not been clarified, and
has so far been addressed by very few studies [10,11].
Recently, it was described that EMT has strong and significant
associations with multiple end points of prostate cancer
progression and cancer-specific death [12]. It is therefore
interesting to establish an EMT model based on prostate cells
in vitro. EMT has been described in prostate cancer cells,
including LNCaP [13,14], DU145 [15] and PC3 cells [16–18].
However, multiple genomic rearrangements have accumulated in
these cell lines during long term passages in different laboratories,
and they are likely to differ significantly from the original patient
cells. For PC3 cells, e.g., both mesenchymal to epithelial transition
(MET) [19] and EMT has been reported. More exact analysis of
EMT will benefit much from cell lines that are very close to
prostate cells in vivo.
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3368EP156T is a primary prostate cell line immortalized by
retroviral hTERT expression and retains many features of the
prostate basal cell phenotype [20]. In an attempt to select for
cells insensitive to contact inhibition [21,22], EMT was observed
in EP156T cells accompanied by loss of contact inhibition, and
these changed new cells were named EPT1. The progeny EPT1
cells exhibited a distinct morphology and increased migration
and invasion compared with the parental EP156T cells, and
gene expression analysis revealed a striking number of gene
expression changes previously found as markers of EMT
[2,9,10,23,24]. Downregulation of E-cadherin (CDH1) and
upregulation of N-cadherin (CDH2) - the so called cadherin-
switch - were most evident in EPT1 cells. It appeared that entire
gene modules involved in cell-to-cell and cell-to-matrix interac-
tions changed their transcription patterns in a coordinated
manner in EPT1 cells. Transformation assays revealed,
however, that EPT1 cells still were serum and growth factor
dependent and had not acquired ability to anchorage indepen-
dent cell growth. This model therefore allows a study of EMT in
primary prostate cells and separated from full malignant
transformation.
Results
EP156T cells lost contact inhibition after long term
culture at high confluence
The EP156T cell line is a primary prostate epithelial cell line
immortalized by hTERT and has been previously characterized
[20]. EP156T cells exhibit a significant pattern of authentic
prostate-specific features with the capacity to differentiate into
glandular buds that closely resemble the structures formed by
primary prostate epithelial cells. It has previously been shown
that ectopic expression of hTERT may be sufficient to
immortalize cells in vitro, but not sufficient to achieve transfor-
mation [25]. This is consistent with the behaviour of EP156T
cells, which exhibited properties of primary prostate basal cells
[20]. EP156T cells grow in a monolayer and cease proliferation
upon reaching confluence, a phenomenon referred to as cell
contact inhibition.
Loss of contact inhibition is one feature of malignant
transformation [26]. One approach of transformation is to select
cells that are insensitive to contact inhibition [22]. In order to
transform EP156T cells to prostate cancer cells, the cells were
kept growing at passage 43 at high confluence to select cells that
survived contact inhibition. Cell death increased once they
reached full confluence. Following 12 weeks thereafter with very
slow proliferation, cells started to grow faster and kept on
dividing and piled up despite high cell density. The changed cells
were named EPT1. The growth curves of EPT1 and EP156T
cells clearly displayed different behavior when cells were grown
at high confluence. Many of the EP156T cells died while EPT1
cells continued proliferation (Figure 1A). Actually, EPT1 cells
can grow on top of each other and pile up even under low cell
density as shown in the DAPI nuclear staining in Figure 1B. Loss
of cell contact inhibition may emerge before anchorage-
independent cell growth and tumour formation in animals
during the transformation process [27,28]. The ability of EPT1
cells to override contact inhibition suggested development in the
direction of transformation.
EMT emerged during the change from EP156T to EPT1
Apart from their loss of contact inhibition, EPT1 cells changed
significantly in morphological features compared with EP156T
cells. EP156T cells have a very clear and round boundary with
individual cells abutting on each other in a uniform array. There
are regularly spaced cell to cell junctions and adhesions between
neighbouring cells (Figure 2A). Very differently, EPT1 cells have
a much longer and irregularly scattered cell shape, character-
istically varying in composition and density like mesenchymal
cells (Figure 2A) and corresponding to known features of
epithelial to mesenchymal transition [2]. The morphological
traits of EMT were consistent with key differences between
EP156T and EPT1 cells regarding E-cadherin and N-cadherin
gene expression as shown in Figure 2B–D and detailed below.
hTERT was expressed at similar levels in both EP156T and
EPT1 and the exogenous nature was supported by very high
puromycin resistance of these cells, which is consistent with
hTERT expression from a puromycin resistance retroviral vector
(data not shown) [20]. EPT1 cells were trypsinized and
propagated in standard EP156T medium with FCS increased
to 5%.
Increased migration and invasion of EPT1 cells
EMT is characterized by increased motility and gain of
invasiveness. To determine whether EPT1 cells had become more
active in migration and invasion than the EP156T cells, we
evaluated the serum-induced migration of cells using transwell
chamber assays. As shown in Figure 3A, EPT1 migrated through
the pores more than 2.5 fold faster than EP156T cells. The
invasive ability of EPT1 and EP156T cells was examined by the
serum-induced invasion through the transwell extracellular matrix
layer. As shown in Figure 3B, EPT1 cells exhibited 3 fold increase
in invasion compared to EP156T cells after 24 h incubation. The
faster migration of EPT1 compared with EP156T cells was also
confirmed by the wound healing assay for 24 h (Figure 3C).
EP156T cells moved as a sheet en block as described for epithelial
cells, whereas EPT1 cells migrated considerably more dynamically
and moved individually and sometimes left a part of the trailing
region behind as described for mesenchymal cells [2]. All these
results indicated that the EPT1 cells had acquired much higher
ability to migrate and invade during the transition to mesenchy-
mal-like cells in comparison with EP156T cells.
EPT1 cells display striking gene expression switch
patterns characteristic of EMT
To identify gene markers involved in EMT from EP156T to
EPT1 cells, we profiled the gene expression of both cell lines using
the Agilent Human Whole Genome Oligo Microarray, which
contained 44 k probes. There were 965 genes downregulated and
893 genes upregulated more than 3 fold in EPT1 cells compared
with EP156T cells. A number of gene expression changes
associated with EMT varied significantly between EPT1 and
EP156T (Table 1). Loss of E-cadherin (CDH1), the prototypic
epithelial adhesion molecule in adherens junctions, and gain of N-
cadherin (CDH2) are among the main hallmarks of EMT [2].
CDH1 was downregulated 27 fold and CDH2 upregulated 33 fold
in EPT1 cells. The cadherin switch was verified by both real-time
qPCR (mRNA level) and Western-blotting (protein level)
(Figure 2B–C). Immunofluorescence staining showed very clearly
the disappearance of E-cadherin and gain of N-cadherin in the
membrane of EPT1 cells (Figure 2D). The epithelial markers
including cytokeratin 14 (KRT14), KRT5 and p63 that charac-
terized EP156T [20], were all downregulated more than 100 fold
in EPT1 cells. In contrast, many mesenchymal markers were
upregulated in EPT1 cells, including cadherin 11 (CDH11),
vimentin (VIM) and fibronectin (FN). Apart from these EMT
markers, several transcription factors that are known to regulate
EMT and Transformation
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EPT1 cells (Table 1).
Entire modules of genes encoding structural
components of cell junctions and attachment were
changed in EPT1
Cell junctions, especially adherens junctions, tight junctions and
desmosomes, are required for the epithelial phenotype and
keeping neighbouring epithelial cells strongly attached to each
other [29]. The dynamic formation and dissolution of cell-cell
junctional complexes is a central process during EMT [3]. Apart
from the adherens junctions mentioned above, dissociated tight
junctions [30,31] or desmosomes [10] were reported as important
features of EMT, respectively.
Using Agilent Whole Human Genome Microarray data, we
compared the expression patterns of genes involved in adherens
junctions, tight junctions and desmosomes between EP156T cells
and EPT1 cells. As shown in Table 2, the majority of the
examined components of these three groups were expressed at a
much lower level in the EPT1 cells than in the parental EP156T
cells (Table 2), such as E-cadherin, P-cadherin, b1 and d1 catenins
in adherens junctions, claudin 1, 4 and 7 in tight junctions,
desmoglein 2 and 3 and desmoplakin 2 and 3 in desmosomes.
Very interestingly, it was also revealed that genes encoding
other structural components of cell junctions were significantly
downregulated in EPT1 compared to EP156T cells (Table 2). Gap
junctions connect the cytoplasms of adjacent cells through the end-
to-end docking of single-membrane structures. Most of the
Figure 1. EPT1 cells have lost contact inhibition. A. Representative growth curves of EP156T and EPT1 cells. Both EP156T and EPT1 cells (3610
3)
were seeded into 96-well plates and cultured in medium containing 1% FCS. Medium was changed every 3 days. At the indicated days (D) MTS
reagent was added directly to culture wells and cell proliferation was calculated from the absorbance at 490 nm following incubation for 3 hours at
37uC. Data are presented as the average OD490 in three independent experiments. B. DAPI nuclear staining of EP156T and EPT1 cells at low density
(a, c) and high density (b, d). White arrows indicate overlapping nuclei. White bars indicate 10 mm.
doi:10.1371/journal.pone.0003368.g001
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ically reduced expression in EPT1 cells (Table 2). Hemidesmo-
somes and focal adhesions are required for epithelial cells to attach
to the underlying basement membrane. Most components of the
hemidesmosomes were downregulated in EPT1 cells compared
with the parental cells, especially dystonin and keratins. Compo-
nents of the focal adhesions were also changed in EPT1 cells
(Table 2).
These observations, together with the consistently changed
EMT markers, indicated that the regulation of EMT was
orchestrated not only in cell phenotype transition, but also in
entire modules of cell junctions. The complete changes of cell
junctions make EPT1 an ideal model to study the complex
regulatatory networks of EMT.
EPT1 cells display gene expression patterns in common
with prostate cancer cell lines
EMT has been frequently observed in transformed cell lines.
We asked if EPT1 cells have similar gene expression profiles as
prostate cancer cells represented by PC3 and DU145. Differen-
tially expressed genes between EP156T and EPT1 and between
EP156T and prostate cancer cell lines were compared. In total
1858 genes differed more than 3 fold between EPT1 and EP156T
cells. As shown in Figure S1, most of the genes altered after EMT
in EPT1 cells were also altered when comparing the PC3 and
DU145 to the EP156T cells. More than 70% of the downregulated
genes in EPT1 overlapped with genes underexpressed in PC3 cells
compared to the EP156T cells. Interestingly, in PC3 cells many
epithelial markers including E-cadherin and the cytokeratins
KRT4 and KRT5 were also significantly downregulated, and the
mesenchymal markers including N-cadherin were also upregu-
lated. This is consistent with a previous report that PC3 cells are
mesenchymal-like cells that can be induced to mesenchymal to
epithelial transition (MET) by overexpression of secreted Frizzled-
related protein 3 (sFRP3) [19]. Both the loss of contact inhibition
of EPT1 and the similar gene expression changes of EPT1 and
prostate cancer cells versus EP156T cells indicated a development
towards transformation of EPT1 cells.
EPT1 cells are not transformed although they have
undergone EMT
The observation that changed genes in EPT1 share patterns
with prostate cancer cell lines made us ask whether EPT1 cells
were transformed. An ability to survive and proliferate under
serum-free condition is one of the well-known features of cancer
cells in vitro [32]. We examined the proliferation of EPT1 cells in
medium with different concentrations of fetal calf serum (FCS). As
shown in Figure 4A, both EP156T and EPT1 cells grew much
slower in 1% FCS than in 5% FCS and completely stopped
growing and died in medium without FCS after 48h incubation,
while prostate DU145 cancer cells still grew well in FCS-free
medium although slower than in complete medium. The long
Figure 2. EPT1 cells have undergone EMT. A. Representative light microscopic images show morphological changes of EPT1 cells derived from
EP156T cells at both low density (a, d) and high density cultures (b, c, e, f). EPT1 cells are fusiform and much longer than EP156T cells. Overlapping
growth of EPT1 cells is also shown (d, e, f). B. Real-time qPCR showing the cadherin switch of mRNA levels in EPT1 compared to EP156T using TaqMan
assays for E-cadherin (Hs00170423_m1) and N-cadherin (Hs00169953_m1). C. Western blots show the cadherin switch of protein levels. Both primary
antibodies against E-cadherin and N-cadherin (BD Transduction Labs.) were diluted 1:2500. The anti-actin mouse Mab was diluted 1:250. The HRP-
conjugated anti-Ig was diluted 1:8000. Molecular weights (kD) were estimated based upon the ECL DualVue Marker in wells labelled M. D. Indirect
immunofluorescence images (206) show decreased E-cadherin and increased N-cadherin in EPT1 cells (right panels). The primary antibody against E-
cadherin was diluted 1:50 and against N-cadherin (BD Transduction Labs.) 1:25 and the FITC-conjugated secondary antibody 1:250.
doi:10.1371/journal.pone.0003368.g002
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looked more vigorous in medium containing 5% FCS than in the
standard EP156T medium, so the concentration of FCS in the
medium for EPT1 cells was adjusted from 1% to 5%.
One of the most important capabilities of cancer cells is self-
sufficiency in growth signals [33]. The complete medium of
EP156T and EPT1 cells contained many kinds of growth factors
including bovine pituitary extract, insulin and EGF [25]. When
the EP156T and EPT1 cells were cultured in basic medium
without the above growth factors, most of the cells in both cell lines
stopped to proliferate and died after 48 h, while the parallel cells in
complete medium grew well (Figure 4B).
Anchorage-independent growth is considered a hallmark of
transformed cells [34,35]. We tested anchorage-independent
growth of EPT1 cells in soft agar. Following 7 days incubation
in soft agar, neither EP156T nor EPT1 cells were able to form
colonies in contrast to positive control DU145 cells (Figure 4).
Although neither formed colonies in soft agar, a difference was
observed. Nearly half of EPT1 cells divided during the first 3 days,
but then proliferation stopped without colony formation in the
end. In contrast, EP156T cells did not divide at all in soft agar.
These differences in soft agar growth suggested that EPT1 cells are
in a stage of premalignancy following EMT (Figure 4). EMT and
transformation assays of EPT1 are summarized in Table 3.
Figure 3. Migration and invasion of EP156T and EPT1 cells. The migration (A) and invasion (B) abilities of EP156T and EPT1 cells were
examined as described in methods. Data are presented as the average OD560 of migrating cells (A) or invading cells (B) in four independent
experiments. C. Representative light microscopic images (106) show increased migration into a wound line of EPT1 compared to EP156T cells.
doi:10.1371/journal.pone.0003368.g003
EMT and Transformation
PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3368Cytogenetic analysis of EP156T and EPT1
Abnormal karyotypes are typically observed in transformed
prostate epithelial cells [36–38]. By G-banding we found no
pronounced chromosomal alterations occurring between EP156T
and EPT1 cells (Figure S2). Most likely a clonal selection has
occurred as the EPT1 cells did not show any of the additional
marker chromosomes. Both the EP156T cells and the progeny
EPT1 cells harboured a marker chromosome which by FISH
(fluorescent in situ hybridization) analysis was shown to be a
derivative chromosome 20 (der(20), Supplementary Figure 2),
Whether gain of der(20) occurred prior to immortalization or as a
consequence of EP156T immortalization is unknown. However, a
gain of chromosome 20 was found in both non-malignant and
malignant cells immortalised by hTERT [39]. As this gain is not a
common finding in prostate cancer [40–42] this could result from
the immortalization process.
Discussion
This work is the first report of an EMT model based on primary,
immortalized prostate epithelial cells. The derivation of EPT1 from
EP156T was clearly verified by the similar expression levels of
hTERT, the puromycin resistance and the very similar karyotypes
of both cell lines, including a common derivative chromosome,
der(20). Several ways to induce EMT in prostate cancer cells have
been described, including overexpression of CAV1 and ID1 or
MMP14 in LNCaP cells [13,14], EGF treatment of DU145 cells
[15], depletion of PDEF [16] or BMP7 treatment of PC3 cells [18].
However, some of these studies cannot easily be reconciled, such as
both EMT and MET induction of PC3 cells [16–19]. Long term
passages of these cell lines in different laboratories may cause them
to differ significantly from the original patient cells, and new models
closer to prostate tissue are desirable.
EMT is not easily observed in histological examinations of
cancer tissue sections, even by experienced pathologists [2,43].
This has led to the idea that EMT may be transient during cancer
progression [44,45] or occur only in a subpopulation of the
tumour cells, such as cells at the invasive front [5,8,46–48] or
cancer stem cells [11,49,50]. The successful establishment of an
EMT model based on primary prostate cells with many traits of
the prostate basal cell phenotype is important in light of a recent
report on the significance of EMT in prostate cancer[12].
EMT has been considered an event following malignant
transformation to endow cancer cells invasive and metastatic
competence [6,8,9]. The present work shows that primary prostate
epithelial cells underwent complete EMT, while most of the
transformation assays remained negative, including serum and
growth factor independent growth, as well as anchorage
independent growth and chromosome instability (Figure 4). At
the same time, loss of contact inhibition combined with similar
differential gene expression patterns as in prostate cancer cell lines
indicated that EPT1 cells are in the early steps towards
transformation. Regarding the temporal relationship between
transformation and EMT, one recent report has also observed that
EMT emerged at a very early stage of transformation (early HF1
cells) [10]. However, EMT in that system was far from full
completion, lacking mesenchymal characteristics in both early and
later transformation stages, and the downregulation of E-cadherin
was significant neither in early (0.960.1) nor in later (0.560.2)
stages of transformation, and N-cadherin was not found
upregulated. To our knowledge, EPT1 cells represent the first
model in which EMT has finished completely at very early stages
of malignant transformation.
It has previously been shown that ectopic expression of hTERT
may be sufficient to immortalize cells in vitro, but not sufficient to
achieve, anchorage-independent cell growth or tumorigenesis
[25]. Full malignant transformation is a stepwise process and can
be achieved by additional expression of oncogenes such as the
SV40 early region plus activated RAS [25,51]. EMT was induced
in the hTERT immortalized primary prostate epithelial EP156T
cells without exogenous introduction of oncogenes and without
transformation. Furthermore, karyotype analysis revealed that the
EPT1 cells were diploid and apparently contained much less
karyotypic abnormalities than previously described for the prostate
cancer cell lines LNCaP, PC3 or DU145 [52,53]. This work shows
that EMT itself appears as a coordinated gene expression program
that may be switched on in either non-transformed or transformed
cells. It is possible that EMT may contribute towards malignant
transformation in non-transformed cells, and that in transformed
cells EMT may contribute to a more aggressive phenotype.
Genomic features of transformation such as loss of heterozygocity
or chromosomal rearrangements cannot easily be reversed. In this
respect EMT regulation may provide an important target for
cancer therapy. Work is ongoing to further transform EPT1 cells
by additional stimulation or oncogene introduction. This model is
therefore valuable for understanding the mechanistic relationship
between EMT and transformation.
EPT1 cells lost contact inhibition accompanied by EMT during
the selection of cells insensitive to full confluence. EP156T cells
ceased growing once cells abutted on each other in contrast to
EPT1 cells whose protrusions passed across neighbouring cells,
eventually leading to heaps of cells. It is still unknown what
happened first or emerged simultaneously in EPT1 cells. Actually,
Table 1. Known markers of epithelial and mesenchymal cells
were changed in EPT1 cells.
Genes
Fold change
EPT1/EP156T p-value References
Epithelial cell markers
CDH1 228 3E-6 Kim JB [62]
CDH3 2138 2E-10 Jarrard DF [63]
DSP 29 6E-5 Savagner P [64]
OCLN 27 5E-3 Medici D [65]
KRT5 2538 4E-11 Kogan I [20]
KRT14 232 2E-13 Kogan I [20]
Mesenchymal cell markers
CDH2 33 1E-10 Lee JM [2]
CDH11 6 1E-14 Sarrio ´ D [67]
FN1 4 7E-3 Yang Z [68]
VIM 3 13E-3 Billottet C [69]
FBN1 74 8E-15 Kiemer AK [23]
FGF1 3 2E-6 Billottet C [69]
FGFR1 9 1E-12 Acevedo VD [66]
SPARC 6 2E-2 Gotoh N [70]
Known regulators of EMT
TWIST2 3 9E-5 Yang J [71]
WNT5A 4 1E-4 Dissanayake SK [72]
BMP4 3 1E-3 Theriault BL [73]
FZD7 3 1E-3 Vincan E [74]
ZEB1 3 10E-12 Eger A [75]
doi:10.1371/journal.pone.0003368.t001
EMT and Transformation
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EMT are associated with cell to cell junctions [54]. The gene
expression of entire modules of cell junctions such as adherens
junctions, gap junctions, tight junctions, desmosomes and
hemidesmosomes were downregulated almost simultaneously as
EPT1 arose from EP156T cells. These cell junction modules not
only can contribute to the interaction of epithelial cells and
provide a barrier against increased migration and invasion in
EMT[2], but also can lead to cell contact inhibition based on cell
communication [55]. It has been shown that adherens junctions
play an important role in contact inhibition of cell growth [56] and
components of gap junctions induce cell contact growth inhibition
[57]. One recent publication showed that EMT mediated loss of
contact inhibition in hepatocarcinoma cells, and reexpression of E-
cadherin restored cell-cell contacts [58]. Work is ongoing to
identify the key regulatory mechanisms behind the observed
switches of entire functional gene expression modules in EPT1
during EMT and the relationship between loss of contact
inhibition and EMT in EPT1 cells.
Materials and Methods
Antibodies, cell lines and cell culture
Mouse monoclonal antibodies were used to detect E-cadherin
(BD Transduction Labs., BD Biosciences, San Jose, CA USA,
Cat#610181), N-cadherin (BD Transduction Labs. Cat# 610920
and Abcam, Cambrigde, GB, Cat.#ab19348) and b-actin (Abcam
Cat# ab11003). The prostate cancer cell lines DU145 and PC3
were obtained from the American Type Culture Collection
(ATCC, Rockwell, MD, USA). The derivation and growth
conditions for the EP156T cell line have been described [20].
Additional reagents were from Sigma-Aldrich, St. Louis, MO,
USA unless indicated otherwise.
Generation of EPT1 cells
EP156T cells were allowed to grow to full confluence at passage
43 in 6 well plates in EP156T standard medium essentially as
described [20]. This medium was modified MCDB153 (Biological
Ind. Ltd, Israel) and was supplemented with 1% MEM non-
essential amino acids solution, 200 nM hydrocortisone, 10 nM
triiodothyronine, 5 mg/ml insulin, 5 mg/ml transferrin, 5 mg/ml
sodium selenite, 100 ng/ml testosterone, 5 ng/mL EGF, 50 mg/
mL bovine pituitary extract (Invitrogen), 100 U/ml penicillin,
100 mg/ml streptomycin and 1% fetal calf serum (FCS). The
Table 2. Expression of cell junction genes in EPT1 cells.
Genes Fold change EPT1/EP156T p-value
Desmosome
DSG2 22 1.9E-3
DSG3 293 7.0E-7
DSC2 28 2.7E-7
DSC3 26 7.7E-7
DSP 29 1.5E-3
JUP 218 2.9E-7
PKP1 27 7.2E-6
PKP2 26 4.0E-7
PKP3 219 5.0E-9
PPL 239 4.9E-5
EVPL 22 1.0E-4
Adherens junction
CDH1 224 6.9E-8
CDH2 33 1.0E-8
CDH3 2120 6.5E-8
CTNNB1 23 8.0E-4
CTNND1 22 1.7E-3
Nectin 4 2.5E-6
Gap junction
GJB2 220 7.7E-7
GJB3 287 7.3E-10
GJB4 217 3.8E-7
GJB5 236 6.0E-10
GJB6 239 5.8E-6
Tight junction
CLDN1 23 2.5E-2
CLDN4 22 9.6E-4
CLDN7 220 1.2E-5
OCLN 24 4.8E-3
Hemidesmosome
DST 237 5.1E-8
KRT4 23 4.2E-2
KRT5 2538 3.5E-11
KRT 13 212 1.2E-4
KRT 14 232 2.2E-13
KRT 15 244 8.6E-15
KRT 16 242 3.3E-4
KRT 17 2177 2.0E-7
KRT 23 241 5.0E-4
COL17A1 278 3.2E-5
ITGB4 211 2.5E-5
Focal adhesion
CAV1 23 9.8E-4
LAMA3 211 4.3E-5
LAMA5 24 5.0E-5
ITGB4 211 2.5E-5
ITGB6 26 2.6E-6
ITGB8 25 1.0E-5
PFN1 22 2.0E-3
Genes Fold change EPT1/EP156T p-value
PTK2 22 1.7E-6
PTK2B 25 4.1E-2
CFL2 6 3.3E-5
ENAH 2 2.4E-5
ITGA11 4 4.6E-9
LPXN 3 3.3E-5
PARVA 2 2.8E-3
TLN2 2 1.2E-5
Expression changes of cell junction genes in EPT1 cells according to Agilent
Human Whole Genome Oligo Microarrays. Results were presented as fold
change compared with EP156T cells. GAPDH expression is given as internal
control. Three arrays were done for each cell type. Minus fold change represents
underexpressed genes in EPT1 cells.
doi:10.1371/journal.pone.0003368.t002
Table 2. Cont.
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trypsinated and transferred to new plates and grown in EP156T
medium with FCS increased to 5%.
Proliferation, migration, invasion and wound closure
assay
For the proliferation assay, 3500 cells in complete medium were
added to each well of the 96-well plate. After time course
incubation, cell proliferation was assayed using the CellTiter96-
HAQueous One Solution Cell Proliferation Assay (MTS) (Promega,
Madison, WI, USA). MTS reagent was added directly to culture
wells, and following incubation for 3 h at 37uC absorbance was
recorded at 490 nm using a 96-well plate reader (Powerwave
spectrophotometer). For trans-well migration assays and invasion
assays, 1.8610
5 overnight serum starved cells in serum-free
medium were added to the top chambers of 24-well trans-well
plates (8 mm size, Cell Biolabs Inc., San Diego, CA, USA) and
media containing 10% fetal calf serum (FCS) were added to the
bottom chambers. Incubation was for 12 h in the migration assay
and 24 h in the invasion assay. Top (nonmigrating) cells were
removed, bottom (migrating) cells were stained and absorbance
was recorded at 560 nm. All of these assays were done in triplicate
and the data are presented as the average absorbance of migrating
cells and invading cells.
For the scratch wound closure assay, 5610
5 cells were seeded in
6-wells. A wound was incised 24 h later in the high density area,
detached cells were removed and fresh medium was added. Photos
were taken of the wounded area at indicated time points.
Microarray analysis and real-time quantitative PCR
Total RNA was extracted from subconfluent monolayers of
cells. One mg of DNAse-treated total RNA was converted into
cDNA and next to Cy3-labeled cRNA using the Low RNA Input
Linear Amplification Kit PLUS, One-Color kit (Agilent Tech.,
Santa Clara, CA, USA), according to instructions. The Agilent
Human Whole Genome (4644 k) Oligo Microarray with Sure
Figure 4. Transformation assays of EPT1 cells. A. EP156T, EPT1 and DU145 cells were cultured in medium containing 0%, 1% and 5% FCS,
respectively. B. EP156T and EPT1 cells were cultured in the absence (GF2) or presence (GF+) of growth factors in the medium. C. Assay of anchorage
independent growth a. Representative images (106) of colony formation in soft agar at different times as indicated. During the first 3 days, some
EPT1 cells kept dividing while EP156T did not. Neither EP156T nor EPT1 cells could grow in soft agar eventually, while many colonies formed in
prostate cancer DU145 cells. b. Following 7 days incubation in soft agar cells were quantified as absorbance at OD570 nm as described in methods.
doi:10.1371/journal.pone.0003368.g004
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used to analyze samples in the present study. The hybridization
and features extraction were described in [59]. Significant Analysis
of Microarray (SAM) using the significantly up- or downregulated
genes in EPT1 cells were performed in J-Express (www.molmine.
com) [60]. Annotated microarray data were uploaded in the BASE
database and formatted and exported to ArrayExpress at the
European Bioinformatics Institute (http://www.ebi.ac.uk/
arrayexpress (Accession number: E-BASE-8)) in agreement with
the MIAME guidelines. Differentially expressed genes in micro-
array data were confirmed by real-time quantitative reverse
transcription PCR (qPCR) using TaqMan assays (Applied
Biosystems, Foster City, CA, USA) and mean quantitative values
were normalized according to ACTB expression as described [59].
Indirect immunofluorescence and Western blot assays
Indirect immunofluorescence (IF) and western blot (WB)
analyses were done essentially as previously described [61]. For
IF cells were grown on 10 mm Assistant glass coverslips in 24 well
plates, then washed with PBS, fixed (4% fresh paraformaldehyde
in PBS for 20 min. at room temperature), permeabilized (0.5%
Triton X-100 for 10 min.), blocked (100 mM glycin for 10 min)
and stored (100% methanol at 4uC) with PBS wash between each
step. Following blocking with 0.5% BSA/PBS for 15 min. primary
mouse monoclonal antibodies were added overnight at 4uCa t
indicated dilutions in 0.5% BSA/PBS. The FITC-labelled
secondary anti-mouse Ig (SouthernBiotech, Birmingham, AL,
USA, Cat# 4050-02) was added for 1 h at room temperature in
0.5% BSA/PBS. Coverslips were mounted in SlowFade with
DAPI (Molecular Probes, Invitrogen, Carlsbad, CA, USA) on glass
slides and analysed using Leica confocal microscopy.
For WB analysis cells were lysed in 200 mM Tris.Cl pH 6.8,
13% ultrapure glycerol, 3.2% b-mercaptoethanol, 40 g/l SDS and
Protease Inhibitor Cocktail Set I diluted 1:100 (Calbiochem, Cat#
535142). Protein concentrations were measured using the BCA
protein Assay kit (Pierce, Rockford, IL, USA, Cat# 23227), and
20 mg protein lysates were separated by 10% polyacrylamide gel
(Biorad Labs., Hercules, CA, USA, Cat#161-1173) SDS electro-
phoresis followed by blotting to PVDF membranes (GE Health-
care Life Sciences, Uppsala, Sweden, Cat# RPN1416F). Primary
mouse monoclonal antibodies and HRP-labelled secondary
antibodies (GE Healthcare, Cat.# NA931) were used at the
indicated concentrations and the bands detected using enhanced
chemiluminescence (GE Healthcare, Cat# RPN2132) and the
Biorax Fluor-s multiImager. Molecular weight markers used were
ECL DualVue Marker (GE Healthcare, RPN810) and Magic-
Mark XP Western Protein Standards (Invitrogen, Cat# LC5602).
Serum independent, growth factors independent assays
For the serum independent assay, cells were cultured in medium
with 0%, 1% and 5% FCS, respectively. For the growth factors
independent assay, cells were cultured in basic MCDB medium
and complete medium, respectively [20]. The proliferation of each
group was measured 48 h later as described above.
Anchorage-independent growth assay
The anchorage independent growth was examined in soft agar.
50 ml of base agar matrix (Cell Biolabs; CytoSelect
TM Cell,
Colorimetric kit) was added in the bottom of each well of a 96-well
plate. When the agar was solid, 75 ml of cell suspension/soft agar
matrix containing 3000 cells was layered on top followed by 50 ml
of 26 complete medium. After 7 days of incubation, the agar
matrix was solubilized and cells stained and absorbance was
recorded at 570 nm. Data show the quantification of proliferation
of EPT1 cells, EP156T cells and positive control DU145 cells in
the soft agar assay.
Cytogenetic analysis
Prior to harvesting, the cells where treated with 20 ng/ml
colcemid for 25 min at 37uC followed by trypsination. The cell
suspension was washed once before exposing the cells to
prewarmed (37uC) hypotonic solution (0.22% (v/v) NaCl,
0.3 mM KH2PO4,8 0 m MN a 2HPO4, pH 8.0). Cells were
pelleted and re-suspended in 4 ml fresh fixative (3:1 methanol:a-
cetic acid) which was repeated four times before storing the cell
suspension at 220uC. G-banding was performed by the standard
Giemsa staining procedure and metaphase spreads were analysed.
The karyotype was described according to ISCN 2005. FISH
(fluorescent in situ hybridization) analyses using probes (CEN20,
TEL12q, LSI MLL) from Vvsis (Abbott Molecular–Vysis, Des
Plaines, IL; Abbott Diagnostics, Maidenhead, UK) were per-
formed according to the manufacturer’s instruction.
Supporting Information
Figure S1 Hierarchical clustering analysis of differentially
expressed genes among DU145, PC3, EP156T and EPT1 cells.
In total 1858 genes differed more than 3 fold between EPT1 and
EP156T cells. The red and the blue represent low expression and
high expression, respectively.
Found at: doi:10.1371/journal.pone.0003368.s001 (4.20 MB TIF)
Figure S2 G-banding of metaphases of the EP156T cells (A)
showed few chromosomal aberrations compared to prostate cancer
cell lines. A marker chromosome was found in all cells (der(20), red
arrow), but diverging clonal evolution as often seen in cell lines was
also seen in the EP156T cells. One subclone had trisomy 13 (blue
arrow), another loss of chromosome 8 and 20 and gain of
chromosome 2, whereas others showed different marker chromo-
somes. The composite karyotype can be described as 46–
48,XY,+2[2],28[3],+13[4],220[2],+der(20)[10],+mar[3][cp10]. G-
Table 3. Summary of EMT and transformation assays of EPT1
cells.
EMT Yes or No
In vitro functional markers
Elongation of cell shape Yes
Increased scattering Yes
Increased migration Yes
Increased invasion Yes
Increased mesenchymal markers
N-cadherin/Vimentin/Fibronectin/Integrin Yes
Decreased epithelial markers
E-cadherin/Desmoplakin/Cytokeratin/Occludin Yes
Transformation Yes or No
Loss of contact inhibition Yes
Chromosomal instability No
Serum independent growth No
Self-sufficiency in growth signals No
Anchorage independent growth No
doi:10.1371/journal.pone.0003368.t003
EMT and Transformation
PLoS ONE | www.plosone.org 9 October 2008 | Volume 3 | Issue 10 | e3368banding analysis of the EPT1 cells (B) showed the same marker
chromosome in all as found in the EPT156 cells (red arrow) but in
addition a loss of the normal chromosome 20 (black arrow). Clonal
evolution involving chromosome 13 (blue arrow) was also found.
The composite karyotype can be described as: 46–47,XY,+13[3],
+i(13)(q10)[2],der(20)[10],221[3][cp10]. In order to gain more
information on the source of the marker chromosome FISH analysis
(C) was performed. A probe against centromer 20 revealed that the
marker chromosome was a chromosome 20 derivative (der(20), red
arrow), whereas a probe against the subtelomeric region of 12q
showed no involvement of that chromosome.
Found at: doi:10.1371/journal.pone.0003368.s002 (2.76 MB TIF)
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